Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ
July 09 2020 - 7:00AM
Houston, Texas and Tuebingen, Germany, July
9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a
clinical-stage biopharmaceutical company active in the discovery
and development of T cell redirecting cancer immunotherapies, today
announced changes to its Board of Directors in conjunction with its
recent listing on NASDAQ. Michael Atieh, Paul Carter, Heather Mason
and Adam Stone will join the Company’s board as new members.
Christof Hettich, L.L.D. will remain a Board Member and Peter
Chambré will continue to serve as the Chairman of the Board.
Collectively, this group of Directors brings a range of experience
and expertise which will be invaluable to Immatics’ continued
progress as a leader in T cell receptor (TCR)-based
therapeutics.
Peter Chambré, Chairman of Immatics’ Board of
Directors commented: “The interplay between Immatics’ target and
TCR discovery platforms is the foundation of its clinical pipeline
of TCR-based immunotherapies designed to attack solid tumors. I
look forward to working with the Board and the management team at
this formative time in the Company’s development. Our objective
remains to demonstrate that our unique science translates into
improved outcomes for patients and thereby build value for our
shareholders.”
Full biographies for each member can be found on
Immatics’ website.
About Immatics
Immatics combines the discovery of true targets for
cancer immunotherapies with the development of the right T cell
receptors with the goal of enabling a robust and specific T cell
response against these targets. This deep know-how is the
foundation for our pipeline of Adoptive Cell Therapies and TCR
Bispecifics as well as our partnerships with global leaders in the
pharmaceutical industry. We are committed to delivering the power
of T cells and to unlocking new avenues for patients in their fight
against cancer.
For regular updates about Immatics, visit
www.immatics.com. You can also follow us on Twitter and
LinkedIn.
Forward-Looking Statements:
Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the Securities and Exchange Commission (SEC).
Nothing in this presentation should be regarded as a representation
by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as
of the date they are made. Immatics undertakes no duty to update
these forward-looking statements.
- Immatics - Board of Directors Press Release_FINAL
For more information, please contact:
For media enquiries
Gretchen Schweitzer or Dr. Stephanie May
Trophic Communications
Phone: +49 171 185 56 82
immatics@trophic.eu
Investor Relations Contact
John Graziano
Solebury Trout
Phone: +1 646-378-2942
jgraziano@soleburytrout.com
Immatics N.V.
Anja Heuer
Corporate Communications
Phone: +49 89 540415-606
media@immatics.com
Jordan Silverstein
Head of Strategy
Phone: +1 281-810-7545
InvestorRelations@immatics.com
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024